Biogen's recently soaring stock price can be attributed to investor optimism in one of the most stubborn areas of drug development.
Califf spoke about the importance of more data to faster and cheaper drug development at the NewYorkBIO conference.
How Seres CEO Roger Pomerantz went from an infectious disease doctor to mining the microbiome for drugs.
As oncology drugs save or extend the lives of many more patients than anyone could have imagined a few years ago, a new challenge has emerged in the wake of their approval: Selling them to patients scared about their prognosis and alternately ignorant of and skeptical about recent breakthroughs in treatment.
AbbVie reports successful elagolix trial; White House touts short-term insurance plans; Mayo Clinic chief to retire.
IPG 2017 net income drops; Bristol-Myers Squibb inks $1.85 billion deal with Nektar on cancer drug; Merck halts final-stage Alzheimer's drug.
Recruitment for clinical trials has never been easy. New tools and tactics could change that — assuming the sheer volume of information doesn't overwhelm trial organizers.
Novartis Oncology taps Pfizer exec as CEO; healthcare jobs become the largest source of U.S. employment; HHS nominee wary about drug-pricing negotiations
FDA approves first nebulized LAMA COPD treatment; more than 2,000 cancer immunotherapies in development; FDA issues 3D-printing guidance
Technology like this could expand further to form better collaborations between pharma, payers and organized providers.
FDA approves first digital pill; biotech companies race to develop cancer-fighting microbiome drugs; Loxo and Bayer reach $1.55 billion deal for rare cancer drugs
Merck to stop developing hep.-C drugs; FDA approves new Lilly breast-cancer drug; California bill would outlaw co-pay cards
New research suggests that the oft-cited $2.6 billion estimate for bringing a drug to market is significantly overstated.
AstraZeneca to sequence two million genomes; Valeant considering Perrigo CEO as its new chief executive; AMA and PhRMA each spent $6 million on lobbying
Roche's Rituxan generated $7.3 billion in sales in 2015, making it the top-selling orphan drug.